Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Go back to Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy| RITE AID CORPORATION (NYSE: RAD) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $8.30 | |||
| Open | $11.16 | 52 Week Low | $6.33 | |||
| Day High | $0.65 | P/E | 1.91 | |||
| Day Low | $0.65 | EPS | $0.34 | |||
| Volume | 63,391 | |||||
| (NASDAQ: RADX) | Delayed: 1.70 +0.05 (3.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.65 | 52 Week High | $ | |||
| Open | $1.73 | 52 Week Low | $ | |||
| Day High | $1.75 | P/E | N/A | |||
| Day Low | $1.64 | EPS | $ | |||
| Volume | 12,110 | |||||
